Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare News In Brief

This article was originally published in The Gray Sheet

Executive Summary

New-tech intraocular lens: CMS is considering whether Rayner Surgical's C-flex Model 570C intraocular lens meets the criteria for a new class of new-technology IOLs. The designation would provide a $50 payment bonus for lenses implanted for cataracts in ambulatory surgical centers for five years. Rayner Surgical says its product, which was approved by FDA in May 2007, reduces silicone oil adhesion and oil-induced opacification associated with vitreoretinal surgery. CMS questions whether the benefit is clinically demonstrable compared with other IOLs. Under current new-tech IOL classifications, four lenses are eligible for a bonus payment through February 2011 based on their ability to reduce spherical aberrations: Advanced Medical Optics' Tecnis, Alcon's Acrysof IQ, Bausch & Lomb's Sofport AO and STAAR's Affinity Collamer (1"The Gray Sheet" March 19, 2007, In Brief)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel